Overview
Singapore thrives as biomedical sciences hub; government policies, public investments and biomanufacturing facilities of industry giants vital components of growth
Singapore is a leading biomedical sciences hub that has maintained its reputation as a key pillar of the manufacturing industry and distinguished base for skilled talent with an excellent research ecosystem over the years.
This has attracted the attention of some of the best manufacturing plants and leading industry giants such as Pfizer, GSK, MSD, Roche, Novartis and Sanofi, for establishing global manufacturing hubs across the country. The Asia-Pacific (APAC) region is considered to have the third largest pharmaceutical market in the world, comprising five emerging biotech hubs, with Singapore being one of them.
The Singapore government plays a vital role in providing the relevant support needed through its policies, regulations and consistent public contributions that facilitate the pharmaceutical industry and its contribution of 5% of the domestic economy’s gross domestic product in 2019. This has allowed the country as a hub to tackle the research and development (R&D), biopharma manufacturing and commercial operations of the APAC region.
In 2019, it was reported that more than 350 biotech companies were established, from startups to small and medium-sized enterprises, while in 2022, more than 25 R&D centres were inaugurated by multinational medical technology companies. These biotech companies depend on the support of top universities and research institutions, specialising in diverse therapeutic areas and modalities.
Tuas Biomedical Park (TBP), a 280-hectare specialised industrial park, was launched in the year 2000, as part of the 1990’s Biomedical Sciences initiative. In 2021, TBP was further developed to manage process development and large-scale manufacturing operations of large companies. As of today, it houses 13 global biopharmaceutical companies and has an overall staff strength of 7,000 employees.
Safety and quality standard schemes and ventures by government regulators and agencies pave way for success of biotech entrepreneurs and enterprises
The increasing growth of biomedical sciences has developed a diversified and talented pool of individuals who have enhanced Singapore’s biotech industry. Government agencies such as the Agency for Science, Technology and Research (A*STAR) were established to assist in the growth of the biomedical industry.
A*STAR is responsible for the development of research that drives scientific discovery and technological innovation. Today, the number of biotech companies inaugurated in Singapore are spin-offs of A*STAR. These biotech companies have the advantage of innovation when fostering one of the largest markets within the country.
However, according to Dr. John E. Connolly, Chief Scientific Officer of Tessa Therapeutics, high risks come alongside significant pay-offs and the development of drugs can go on for a long duration of time, leading to the rising cost of funding resources and acquisition of employees, hindering the most resilient biotech entrepreneurs. It is an indication that the individuals who support these ventures with patience and motivation are the incentive for attracting the attention of global investors.
Additionally, JTC is a government agency responsible for the industrial process and infrastructure that supports the development of growing industries. The JTC Space at TBP offers industrial and laboratory space for pharmaceutical giants suitable for making use of single-use technology (SUT) manufacturing platforms. Basic infrastructure including road networks and utilities are also available for speeding up the set-up times of these giants.
Similarly, the Health Sciences Authority (HSA) is a multifaceted scientific and regulatory government agency responsible for the effectiveness, safety and quality maintenance regulations of drugs, innovative therapeutics, medical devices and health-related products. HSA is also considered the national expert in forensic medicine, forensic science and analytical chemistry testing for the legal system and public health.
Key Trends
Investments made by pharmaceutical and biotechnological companies sustain Singapore’s biomedical manufacturing industry and economy
Singapore gained independence in 1965, earning its reputation as a prospering country with its ever-growing economy. One of the main contributors to Singapore’s economic growth is the exporting of various biotech products. Over a span of ten years up to 2015, Singapore’s biomedical manufacturing industry had risen in value from SGD 6 billion to 23.3 billion, with a contribution of 5% of the domestic economy’s gross domestic product.
While Singapore was ranked by the Bloomberg Health Care Efficiency index 2016 as having one of the most effective healthcare systems worldwide, the country’s initiatives at fostering the biopharmaceutical market will continue to invigorate its status despite the current pressures pharmaceutical and biotechnology companies have been facing. In 2017, GlobalData, a research and consulting firm, reported that a rise in the pharmaceuticals market from SGD 1.28 billion in 2017 to around SGD 1.6 billion in 2021 was expected.
In 2018, it was noted that Singapore’s approach at process R&D faculties of companies was assisting them through enhancing innovation, biologics and small-molecule production. In addition to this, the Biopharmaceutical Manufacturers’ Advisory Council (BMAC), which comprises local pharmaceutical plant site directors and government agencies, would focus on ensuring that Singapore evolves into a top-notch manufacturing economy.
The growing interest and investments made by global giants includes contributions made by GSK, SGD 8 million in funding for research carried out by 14 principal investigators under the GSK-Singapore Partnership for Green and Sustainable Manufacturing (GSM) for specific areas of chemical, physical and bio-transformations, life cycle assessment, facilities and supply chain, equipment and technical operations, and solvent selection and optimisation. Similarly, Bayer Healthcare also invested SGD 14.5 million for five projects in collaboration with local academic institutions to promote the R&D of oncology diagnosis and treatment.
Armed with technology and strong biotech ecosystem, companies battle COVID-19 head-on
In the wake of the COVID-19 pandemic, public and private companies began to rapidly produce innovative solutions, depending on the country’s strong biomedical foundation and diverse innovation ecosystem. Local innovators collaborated to deliver detection methods by way of artificial intelligence (AI), thereby launching human vaccine trials within a span of months, a result of Singapore’s strong health and biomedical science infrastructure, and persistent focus on leveraging innovation.
For methods of preventing the spread of the virus, testing and possible lifesaving treatments, companies are collaborating with public institutions to rely on local expertise, to guarantee the usage of technological inventions to aid in facing the pandemic head-on. In 2020, the utilisation of technology to develop solutions began to trend as numerous initiatives were launched. Ghim Li Group, a local textile company, and Nanyang Technological University (NTU) teamed up to produce a reusable three-ply face mask offering antibacterial filtration facilities - the Ultra Mask.
For detecting asymptomatic carriers, cPass - one of the world’s first rapid serology test kits - was innovated by Duke-NUS Medical School, and further developed and produced by GenScript Biotech Corporation, a biotech company, and A*STAR’s Diagnostics Development Hub. Additionally in 2020, it was noted that in collaboration with the National University Hospital and an industry organisation led by the National Additive Manufacturing Innovation Cluster, the National University of Singapore (NUS) designed three new nasopharyngeal COVID-19 testing swabs.
Singapore is also looking at vaccine solutions and lifesaving treatments such as TY027, developed by Tychan, the Ministry of Defence, Ministry of Health and Economic Development Board (EDB), and COVID-19 antibody treatments by Proteona, a local startup with Australia-based Vaxine and Flinders Medical Centre.
Key Statistics
- From 2011 to 2015, the Singapore government contributed SGD 16.1 billion towards research within the biotech industry, with SGD 3.7 billion worth of funds allocated to enhancing the current research infrastructure.
- In 2021, Sanofi, a pharmaceuticals giant, aimed at investing SGD 630 million over the next five years in the hopes of building a vaccine production centre.
- As of September 2022, GlobalData, a leading analytics company, forecasts an anticipated growth in the medical devices market (5.2% CAGR) from SGD 2.6 billion in 2016 to SGD 3.5 billion in 2022.
Top Singapore MNCs in Biotechnology
ILLUMINA SINGAPORE PTE. LTD.
Repeated Company as per the Client -
JOHNSON & JOHNSON PTE. LTD.
Repeated Company as per the Client -
LABCORP DEVELOPMENT (ASIA) PTE. LTD.
Labcorp Development (Asia) was incorporated in 1996. It is part of the global network of US-based Labcorp Drug Development. The corporation known as Covance is now a subsidiary of Labcorp. The company offers contract research services for the pharmaceutical, medical device and diagnostics, crop protection, and chemical sectors. Through its industry-leading central laboratory business, Labcorp executes tests on more than 3 million patient specimens each week and supports clinical trial activities in nearly 100 countries. Labcorp Development also provides laboratory testing services to the chemical and agrochemical sectors. It is considered a market leader in toxicology services, central laboratory services, discovery services, and Phase III clinical trial management services.
ELI LILLY (SINGAPORE) PTE LTD
Eli Lilly (Singapore) was established in 1994. Its parent company is headquartered in the United States. The wholesale distribution of prescription pharmaceuticals, proprietary drugs, and toiletries forms part of the company's operations. Eli Lilly offers diabetes medications, oncology products, immunology products, neuroscience products, and other treatments. Some of Eli Lilly medications are launched in collaboration with other pharmaceutical businesses. Among Eli Lilly’s 2022 accolades are: America’s Best Employer For Women (Forbes), Disability Equality Index Best Places to Work – Perfect Score (Disability:IN), and Corporate Equality Index – Perfect Score (Human Rights Campaign Foundation).
ABBOTT MANUFACTURING SINGAPORE PRIVATE LIMITED
Repeated Company as per the Client -
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
Takeda is a worldwide biopharmaceutical firm that is patient-focused, values-based, and R&D-driven. Established in 2009, its subsidiary Takeda Pharmaceuticals (Asia Pacific) in Singapore oversees Takeda's Asian sales and marketing divisions. Takeda Pharmaceuticals’ research and development efforts are concentrated in four therapeutic areas: oncology, rare diseases, neuroscience, and gastroenterology. Takeda Pharmaceuticals also invests in focused R&D in Plasma-Derived Therapies and Vaccines, as well as being involved in the provision of healthcare solutions for metabolic, cardiovascular, gastrointestinal, and respiratory issues. Furthermore, the corporation is in charge of directing the local management team's strategic and commercial activities in Australia, Thailand, the Philippines, Indonesia, India and Malaysia.
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
Repeated Company as per the Client -
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Boehringer Ingelheim is a research-driven biopharmaceutical company based in Germany. Boehringer Ingelheim Singapore was incorporated in 2004. The firm is focused on developing life-changing treatments, and creates value via innovation in areas of significant and as yet unmet medical needs. Boehringer Ingelheim covers three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company serves over 130 markets and employs more than 50,000 staff members across the globe. Boehringer Ingelheim is also developing world-class innovations in order to predict, prevent and treat diseases that affect animals.
AMGEN SINGAPORE MANUFACTURING PTE. LTD.
Established in 2012, Amgen Singapore Manufacturing is part of the global network of California-based Amgen, which is one of the world’s leading biotechnology companies. Amgen is devoted to unleashing the promise of biology for people suffering from critical diseases by developing, producing and delivering novel human medicines. Amgen leverages its biologics manufacturing capabilities to look for solutions that enhance health outcomes. The company focuses on six therapeutic areas: oncology/haematology, cardiovascular disease, inflammation, bone health, nephrology, and neurology. Amgen’s subsidiary, deCODE Genetics, is a global leader in human genetics, which has discovered the genetic risk factors for many common illnesses.
ABBVIE OPERATIONS SINGAPORE PTE. LTD.
Incorporated in 2014, AbbVie Operations Singapore is a research-driven biopharmaceutical business with the resources to explore novel therapeutics. It is part of the global network of AbbVie, which is headquartered in Illinois, USA. To create novel solutions that genuinely make a difference, AbbVie Operations cooperates with peers, academics, clinical specialists, front-line practitioners, governments and advocacy organizations. Immunology, cancer, neurology, eye care, virology, women's health, and gastroenterology are among the primary therapeutic areas covered by AbbVie Operations, as are goods and services from its Allergan Aesthetics portfolio. AbbVie Operations works hard to combat neglected tropical diseases (NTDs) that disproportionately afflict the world’s impoverished and vulnerable communities.
Top Singapore Large Local Enterprises in Biotechnology
BIOLIDICS LIMITED
Incorporated in 2009, Biolidics – formerly known as Clearbridge BioMedics – is a medical technology company. Biolidics focuses on the development of cell enrichment systems that, when blended with other analytical tests, have a broad spectrum of applications for cancer diagnosis, prognosis, treatment selection, and treatment monitoring. The company has created unique technologies and solutions that have the potential to serve as a platform for cancer diagnosis, prognosis, therapy selection and treatment monitoring. Biolidics is a National University of Singapore (NUS)/SMART MIT spin-off and the first incubatee of Clearbridge Accelerator, a high-technology incubator supported by the Singapore Government's National Research Foundation (NRF).
BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE. LTD.
Repeated Company as per the Client -
TEMASEK LIFE SCIENCES LABORATORY LIMITED
Temasek Life Sciences Laboratory (TLL), which was founded in 2002, is affiliated to the National University of Singapore and Nanyang Technological University. TLL has an international cooperation network, and collaborates and conducts joint research endeavours with both local and foreign partners. The organization's primary focus is on understanding the molecular mechanisms underlying the growth and physiology of plants, fungi and animals, which serves as the foundation for biotechnology innovation. Temasek Life Sciences Laboratory encourages, conducts, and commercializes breakthrough research, as well as providing postgraduate education in life sciences and biotechnology.
CONSORTIUM FOR CLINICAL RESEARCH AND INNOVATION, SINGAPORE PTE. LTD.
The Consortium for Clinical Research and Innovation Singapore (CRIS) is a wholly-owned subsidiary of MOH Holdings. Established in 2020, it aims to strengthen synergies and develop strategies for national-level clinical research and translation programmes that are under the supervision of the Ministry of Health (MOH). The consortium collaborates with research and biomedical institutions and communities in Singapore's public and private sectors. CRIS brings together the following five entities under a common governance structure: Singapore Clinical Research Institute, National Health Innovation Centre, Advanced Cell Therapy and Research Institute Singapore, Precision Health Research Singapore (PRECISE), and Singapore Translational Cancer Consortium.
MIRXES PTE. LTD.
Repeated Company as per the Client -
Top Singapore SMEs in Biotechnology
ASLAN PHARMACEUTICALS PTE. LTD.
Established in 2010, ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical firm that develops novel therapies to improve patients' lives. ASLAN's portfolio is led by the Eblasakimab and Farudodstat programmes, which are now investigating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor in atopic dermatitis, and ASLAN003, a powerful oral DHODH inhibitor being developed for autoimmune illnesses. ASLAN focuses on diseases that are both common in Asia and rare in the United States and Europe. ASLAN conducts clinical development programmes on a global scale with teams based in Singapore and California. Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL are among ASLAN's partners.
INVITROCUE PTE. LTD.
Incorporated in 2012, Invitrocue is a world-class revolutionary life sciences firm that specializes in generating ground-breaking 3D cell-based models from all solid tumours, such as patient-derived organoids. Invitrocue's Onco-PDO technology allows patient-derived cancer cells to be cultivated in laboratories for testing against a panel of medications to assist tailored treatment decisions. Invitrocue focuses on the development of in vitro and in vivo models to improve the efficacy and safety evaluation of new medications for biotechnology, pharmaceutical, and consumer healthcare companies. Invitrocue is headquartered in Singapore and has offices in Australia, China, Hong Kong and Germany.
HISTOINDEX PTE. LTD.
HistoIndex, established in 2010, is a global MedTech spin-off firm from Singapore's Institute of Bioengineering and Nanotechnology (IBN), and the Agency of Science, Technology and Research (A*STAR). The company focuses on artificial intelligence-based stain-free digital pathology solutions. The digital pathology platform of HistoIndex defines and precisely quantifies fibrosis, steatosis, inflammation, and ballooning, as well as assessing disease development and regression. HistoIndex's imaging products have benefited over 150 hospitals, universities, research institutes, CROs, and drug development businesses worldwide. In 2013, HistoIndex has received the A*Star Scientist Entrepreneur Award, as well as the Red Herring Top 100 Asia and Global Awards.
TESSA THERAPEUTICS LTD.
Tessa Therapeutics, established in 2011, is a clinical-stage biotechnology firm which is developing autologous and allogeneic cell treatments for a variety of malignancies. Tessa Therapeutics’ treatments are based on two novel technologies: CD30-Chimeric Antigen Receptors and a subset of T cells known as Virus-Specific T Cells. In addition, it is working on a novel allogeneic platform technology that combines the distinct features of CD30-CARs and VSTs. Tessa Therapeutics is headquartered in Singapore, where it is also constructing its own cutting-edge commercial production plant. The company is in the process of establishing its US headquarters in New Jersey.
OBSERVATIONAL AND PRAGMATIC RESEARCH INSTITUTE PTE. LTD.
Established in 2014, the Observational and Pragmatic Research Institute (OPRI) conducts high-quality observational research on disease burden and care to enhance patient outcomes. Health economics and outcomes research, drug safety studies, clinical trials, and end-to-end research support services are among the services provided by the institute.Its network of independent businesses is organized around two primary brands: Observational and Pragmatic Research Institute (OPRI) and Optimum Patient Care (OPC). The institute collaborates closely with independent companies to provide commercial access to bespoke databases such as the OPC Research Database.
LION TCR PTE. LTD.
Lion TCR, incorporated in 2015, is a clinical-stage T cell immunotherapy firm headquartered in Singapore. Lion TCR’s main immunotherapy technology platform is focused on developing and commercializing TCR-T cell therapeutics against viral-related malignancies, with hepatitis B virus-related hepatocellular carcinoma and chronic hepatitis B virus infection being the leading product candidate. Cell treatment for cancer and life-threatening infectious disorders is being developed by the company. Lion TCR’s strategy is to develop a global oncology business with a diverse portfolio of engineered TCR treatment candidates with the potential to significantly improve cancer patients' clinical outcomes.
ONE BIOMED PTE. LTD.
Established in Singapore in 2015, One BioMed is a molecular life science company that is committed to improving human health via innovation. It provides biomedical researchers and clinicians with unprecedented access to cutting-edge technologies by inventing and building innovative molecular platforms that are accessible and best-in-class. The company offers an automated sample preparation system for purifying and isolating nucleic acids from a wide range of samples, which is required as the first step in many molecular biology and clinical diagnostic technologies. One BioMed has created a point-of-care diagnostic platform that makes use of two patented technologies: a silicon biophotonics sensor and a chemistry-based nucleic acid extraction.
CELLIGENICS PTE. LTD.
Incorporated in 2016, Celligenics is a biotechnology firm focused on developing future-relevant solutions using stem cell technologies in a revolutionary age of digital medicine. Celligenics believes that research is essential to progress toward novel and upcoming clinical processing and technologies. The company's competence extends to investment finance, enterprise strategy, and product innovation, as well as familiarity with molecular and cell biology. Celligenics develops medical treatment solutions and sells active ingredients to the cosmeceutical industry. The company is developing stem-cell-based therapeutic treatments for a variety of diseases, with a focus on the therapeutic applications market and cosmetic applications.
DOTBIO PTE. LTD.
Established in 2017, DotBio's patented DotBody technology is used to generate immuno-oncology treatments based on humanized domain antibodies. DotBodies are multi-specific, humanized, and very stable domain therapeutic antibodies. The company was formed around the idea of the DotBody technology, based on the competence in protein and antibody engineering at Singapore's Nanyang Technological University. DotBio's platform is based on the rapid prototyping and modular design concepts that have changed sectors such as automobiles, microchips, and construction. DotBio has an ever-expanding bank of DotBody modules that target a range of illness triggers. These include cancer-specific targets, immunological checkpoints, signalling molecules in the tumour microenvironment, and immune cell-specific targets in the tumour environment.
SINGCELL TECH PTE. LTD.
Established in 2021, SingCell Tech is a Singapore-based organization that develops technology for stem cell research. SingCell Tech provides process development and contract production services to clean meat firms. The company owns patented bioprocessing technology created at A*STAR's Bioprocessing Technology Institute. SingCell Tech offers scalable bioprocessing of cell types, including mesenchymal stem cells, myoblasts, and adipose stem cells. SingCell Tech is situated in Biopolis, Singapore, among a cluster of some of Asia Pacific's most innovative research centres and biotechnology enterprises. The company employs its unique 3D microcarrier-based iSPHERES technology in the production of mesenchymal stem cells and induced pluripotent stem cells for preclinical and clinical research.
Top Singapore Fastest-Growing Companies in Biotechnology Companies
MIRXES PTE. LTD.
Repeated Company as per the Client -
HUMMINGBIRD BIOSCIENCE PTE. LTD.
Incorporated in 2015, Hummingbird Bioscience is a clinical-stage biotechnology firm that creates innovative, precision therapies for cancer and autoimmune illnesses, using a patented and differentiated Rational Antibody Discovery (RAD) platform. Organizations that the company has partnered with include A*STAR and MIT. Hummingbird Bioscience's methodology incorporates computational and systems biology, as well as wet lab drug discovery, in a multidisciplinary, collaborative environment that spans initial discovery to clinical development. Hummingbird Bioscience applies this integrated strategy to target identification and patient selection, allowing its team to maximize the efficiency with which innovative scientific ideas are translated while lowering the inherent risk in drug research and development.
AESCULAPE CRO PTE. LTD.
Aesculape CRO, founded in 2010, is a Clinical Research Organization headquartered in Singapore. It provides full clinical trial services to pharmaceutical, medical device, biotech, and nutraceutical firms looking to register and commercialize their products in Europe, the United States and Asia. With a network of clinical trial control offices throughout Eastern, Central, and Western Europe, as well as South East Asia, Aesculape CRO provides a high level of quality in clinical trial execution while offering full service capabilities from Phase I to IV. Aesculape CRO’s skilled staff are experienced in a variety of therapeutic areas and can address all aspects of clinical research, including clinical operations, medical writing, pharmacovigilance, and marketing authorization.
BIOLIDICS LIMITED
Incorporated in 2009, Biolidics – formerly known as Clearbridge BioMedics – is a medical technology company. Biolidics focuses on the development of cell enrichment systems that, when blended with other analytical tests, have a broad spectrum of applications for cancer diagnosis, prognosis, treatment selection, and treatment monitoring. The company has created unique technologies and solutions that have the potential to serve as a platform for cancer diagnosis, prognosis, therapy selection and treatment monitoring. Biolidics is a National University of Singapore (NUS)/SMART MIT spin-off and the first incubatee of Clearbridge Accelerator, a high-technology incubator supported by the Singapore Government's National Research Foundation (NRF).
IGENE LABORATORY PRIVATE LIMITED
iGene Laboratory, which was founded in 2014, is a fully owned subsidiary of INEX Innovate. The Singapore-based laboratory serves medical professionals and patients in the South East Asian region and beyond by providing tests based on technological platforms such as Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR). The Ministry of Health (MOH) in Singapore has licensed iGene Laboratory, and the College of American Pathologists (CAP) has accredited it in Next Generation Sequencing and Molecular Microbiology, including COVID-19 testing services. iGene Laboratory adheres to GenQA and QCMD guidelines.
AUSTRIANOVA SINGAPORE PTE. LTD.
AUSTRIANOVA Singapore, which was incorporated in 2007, is a cutting-edge biotechnology firm that adheres to the highest global quality standards in the manufacturing of cell-based products. AUSTRIANOVA has expertise in Cell Biology, GMP-grade Cell Products, and Living Cell Encapsulation. The company’s Quality System was developed in Germany, and its data is housed at two locations in Switzerland. AUSTRIANOVA Singapore provides a complete solution for cell-based products, from conceptualization and cloning through the development and characterization of cell lines, and the manufacture of material for pre-clinical and GMP clinical studies.
CURIOX BIOSYSTEMS PTE. LTD.
Curiox Biosystems was established in 2008 with the goal of commercializing DropArray. The venture was funded by Nanostart AG and Exploit Technologies, A*STAR's commercialization arm. Curiox Biosystems obtained a big corporate investment in 2010 from the Zicom Group, a Singaporean/Australian conglomerate listed on the Australian Stock Exchange, which significantly sped up its product development timetable and enabled it to expand into worldwide markets. Curiox Biosystems closed a Series B round of fundraising in 2019, raising US$ 15 million from a consortium of Korean venture capital firms including KB Investments, IMM Investments, Quad Investments, HB Investments, DAYLI Investments, and SV Investments. Curiox Biosystems products are centrifuge-free, non-disruptive, flow-based washing systems that are automated.
MACROGEN ASIA PACIFIC PTE. LTD.
Incorporated in 1997, Macrogen Asia Pacific is a fully owned subsidiary of Macrogen, a Korean precision medicine biotechnology business. Macrogen has used a Genetically Engineered Mouse (GEM) for disease and new medicine assessment, the development of molecular diagnosis kits, target treatment research, new medicine research, and gene treatment research using stem cells and induced pluripotent stem cells for the purpose of realizing and implementing precision medicine. Macrogen has purchased over 50 technologies, including the Broad Institute's CRISPR-Cas9 portfolio. In addition, the corporation has consistently supported numerous research and development efforts by local and international life science and medical researchers.
GENOMAX TECHNOLOGIES PTE. LTD.
Genomax Technologies, established in 2003 and headquartered in Singapore, has since expanded to Malaysia and Thailand. Genomax is a vendor of scientific products and facilities that assist life science research communities, biotechnology and pharmaceutical companies, clinical research organizations and hospitals to plan, start and accelerate their research. The company focuses on positioning solutions in five major application categories: bioinformatics, clinical, genomics, molecular cell biology, and proteomics. Genomax provides cutting-edge reagents and consumables from notable providers in antibodies, high-throughput screening (HTS) tests, cell culture, cell sorting, and ELISA Kits. Genomax works with a number of manufacturers on computerized nucleic acid extraction and purification, qPCR, and Next Generation sequencing.
SPHAERA PHARMA PTE. LTD.
Sphaera Pharma, incorporated in 2008, is a global medication discovery and development firm. By creating a balanced portfolio of early stage research projects and clinical programmes, Sphaera Pharma provides novel treatments to people with unmet medical needs. With headquarters in Singapore and subsidiaries in the United States and India, Sphaera Pharma has access to global resources, and experience in a unique model to revitalize medication research and development. Sphaera's India research lab has built in-house expertise in all areas of pre-clinical drug discovery and development. Through its external relationships, Sphaera Pharma has access to specialist services such as radiochemistry, c-GMP manufacturing, GLP investigations, clinical formulations, structural biology, and clinical development.
